Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- BULLETIN
February 2, 2004
- BUSINESS NEWS IN BRIEF
February 2, 2004
- DIAGNOSTIC NEWS IN BRIEF
February 2, 2004
- Annual Business Results
February 2, 2004
- WORLD NEWS IN BRIEF
February 2, 2004
- NHI Price Reductions by Re-pricing Rule Unlikely This Year
February 2, 2004
- Roche Diagnostics Aims to Reach Sales of \60 Bil. in 2008: Mr Ogawa
February 2, 2004
- Newly Launched Generics to Be Applied to 70%- Multiple Rule
February 2, 2004
- Antihistamic Drugs Making Stiffer Competition
February 2, 2004
- REGULATORY NEWS IN BRIEF
February 2, 2004
- Meiji Seika Kaisha Aiming for Record Profits in FY2005
February 2, 2004
- Market-based Healthcare Reform Criticized: Seminar
February 2, 2004
- Korosho Proposes DPC Review Policy
February 2, 2004
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
February 2, 2004
- LTT Bio-Pharma Starts PI Trial on PC-SOD
February 2, 2004
- Generic Drugs Had 13.1% Share of Ethical Sales Volume in FY2002: EPMA
January 26, 2004
- DIAGNOSTIC NEWS IN BRIEF
January 26, 2004
- Kirin's Pharma Division Aims for Sales of \70 Bil. in 2006
January 26, 2004
- Meet the Leaders (30)
January 26, 2004
- Toho to Enhance Solution Proposals to Customers
January 26, 2004
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…